Valion Bio Inc Cash Flow Conversion Efficiency
Valion Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Valion Bio Inc (VBIO) has a cash flow conversion efficiency ratio of -0.444x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.28 Million) by net assets ($11.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VBIO company net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Valion Bio Inc (2010–2025)
Cash flow conversion efficiency of Valion Bio Inc from 2010 to 2025. This chart illustrates how Valion Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VBIO live share price for real-time trading data and today's change.
Valion Bio Inc Cash Flow Conversion Ratio Explained
Valion Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Valion Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valion Bio Inc ranked by their cash flow conversion efficiency. Review Valion Bio Inc (VBIO) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Churchill China plc
LSE:CHH
|
0.013x |
|
Groupimo SA
PA:ALIMO
|
0.025x |
|
Redan S.A.
WAR:RDN
|
-0.002x |
|
Oxford Metrics plc
LSE:OMG
|
0.026x |
|
EGR EXPL LTD
F:Z0R
|
-0.091x |
|
GetBusy PLC
LSE:GETB
|
0.003x |
|
Bentley Capital Ltd
AU:BEL
|
0.187x |
|
Christie Group plc
LSE:CTG
|
0.291x |
Annual Cash Flow Conversion Efficiency for Valion Bio Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Valion Bio Inc from 2010 to 2025. Also see VBIO total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.80 Million | $-7.00 Million | -0.417x | +81.55% |
| 2024-12-31 | $2.54 Million | $-5.72 Million | -2.258x | +5.01% |
| 2023-12-31 | $3.58 Million | $-8.51 Million | -2.377x | +3.24% |
| 2022-12-31 | $3.63 Million | $-8.92 Million | -2.457x | -481.07% |
| 2021-12-31 | $13.27 Million | $-5.61 Million | -0.423x | -116.44% |
| 2020-12-31 | $-1.18 Million | $-3.03 Million | 2.572x | +266.15% |
| 2019-12-31 | $2.37 Million | $-3.67 Million | -1.548x | +82.72% |
| 2017-12-31 | $322.27K | $-2.89 Million | -8.957x | -142.16% |
| 2016-12-31 | $374.37K | $-1.38 Million | -3.699x | -213.68% |
| 2015-12-31 | $-518.16K | $-1.69 Million | 3.254x | +40.47% |
| 2014-12-31 | $-1.08 Million | $-2.50 Million | 2.316x | -88.05% |
| 2013-12-31 | $-110.00K | $-2.13 Million | 19.389x | +571.15% |
| 2012-12-31 | $-570.00K | $-1.65 Million | 2.889x | +895.44% |
| 2011-12-31 | $-90.00K | $-26.12K | 0.290x | +45899.55% |
| 2010-12-31 | $-49.99 Million | $-31.54K | 0.001x | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more